How much funding has Neurogene Inc. raised?

Neurogene Inc. has raised $183.5M in total funding, most recently a Series B round.

Who are Neurogene Inc.'s investors?

Neurogene Inc.'s investors include EcoR1 Capital, RTW Investments, Redmile Group, Samsara BioCapital, Casdin Capital, Cormorant Asset Management.

When was Neurogene Inc. founded?

Neurogene Inc. was founded in 2018.

Where is Neurogene Inc. headquartered?

Neurogene Inc. is headquartered in New York, New York, United States.

What industry is Neurogene Inc. in?

Neurogene Inc. operates in Biotech, Healthcare.

How many employees does Neurogene Inc. have?

Neurogene Inc. has 51-200 employees.

Neurogene Inc.

IPO

Neurogene - Developing Purpose-built Genetic Medicines

Public · New York, United States · Founded 2018 · $183.5M raised

Biotech

Healthcare

Headquarters: New York, New York
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: neurogene.com

Total Funding: $183.5M
Last Round: $115.0M Series BDec 2020
Rounds: 2
Type: Public

About

Neurogene is a clinical-stage gene therapy company advancing genetic medicines for rare neurological diseases, with its lead program NGN-401 targeting Rett syndrome using a proprietary EXACT technology platform designed to overcome dosage-sensitivity limitations of conventional gene therapy approaches.

Summary

Neurogene Inc. is a Biotech company based in New York, United States, founded in 2018. It has raised $183.5M in total across 2 rounds, most recently a $115.0M Series B round in Dec 2020. Investors include EcoR1 Capital, RTW Investments and Redmile Group.

LinkedIn X (Twitter)